ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction

ASGE Standards of Practice Committee; (ASGE Standards of Practice Committee Chair, 2017-2020)

doi:10.1016/j.gie.2020.07.063

ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction

ASGE Standards of Practice Committee, (ASGE Standards of Practice Committee Chair, 2017-2020)

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

This American Society for Gastrointestinal Endoscopy guideline provides evidence-based recommendations for the endoscopic management of gastric outlet obstruction (GOO). We applied the Grading of Recommendations, Assessment, Development and Evaluation methodology to address key clinical questions. These include the comparison of (1) surgical gastrojejunostomy to the placement of self-expandable metallic stents (SEMS) for malignant GOO, (2) covered versus uncovered SEMS for malignant GOO, and (3) endoscopic and surgical interventions for the management of benign GOO. Recommendations provided in this document were founded on the certainty of the evidence, balance of benefits and harms, considerations of patient and caregiver preferences, resource utilization, and cost-effectiveness.

Original language	English (US)
Pages (from-to)	309-322.e4
Journal	Gastrointestinal endoscopy
Volume	93
Issue number	2
DOIs	https://doi.org/10.1016/j.gie.2020.07.063
State	Published - Feb 1 2021

Bibliographical note

Funding Information:
The following authors disclosed financial relationships: A. C. Storm: Consultant for Apollo Endosurgery US Inc, Endo-TAGSS, and Enterasense; data and safety monitoring support from Erbe USA Inc. and GI Dynamics. D. S. Fishman: Contributor payment support for intellectual property from UpToDate. M. A. Khashab: Consultant for BSCI, Olympus, and Medtronic. M. Al-Haddad: Research and teaching support from Boston Scientific. S. K. Amateau: Consultant for Boston Scientific Corporation, Cook Medical LLC, Endo-Therapeutics, Hemostasis LLC, Merit Medical Systems Inc, Olympus Corporation of the Americas, and STERIS Corporation. J. L. Buxbaum: Consultant for Boston Scientific Corporation, Eagle Pharmaceuticals, Inc, Cook Medical LLC, and Olympus America Inc; grant support from Medtronic USA, Inc and Olympus America Inc. C. J. DiMaio: Consultant for AbbVie, Boston Scientific Corporation, and Covidien. L. L. Fujii-Lau: Travel compensation from Ovesco. S. R. Gurudu: Research grant from Gilead Pharmaceuticals. L. H. Jamil: Consultant and speaker for Aries Pharmaceutical. M. S. Sawhney: Stockholder with Allurion Technology, Inc. N. C. Thosani: Consultant for Boston Scientific Corporation, Covidien, and Pentax of America, Inc. J. Yang: Consultant for Olympus. S. B. Wani: Consultant for Boston Scientific, Medtronic, and Interpace; advisory board member for Cernostics.

Publisher Copyright:
© 2021 American Society for Gastrointestinal Endoscopy

PubMed: MeSH publication types

Practice Guideline

Publisher link

10.1016/j.gie.2020.07.063

Find It

Find It at U of M Libraries

Cite this

@article{99d3179483e44bc29d664553361a2488,

title = "ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction",

abstract = "This American Society for Gastrointestinal Endoscopy guideline provides evidence-based recommendations for the endoscopic management of gastric outlet obstruction (GOO). We applied the Grading of Recommendations, Assessment, Development and Evaluation methodology to address key clinical questions. These include the comparison of (1) surgical gastrojejunostomy to the placement of self-expandable metallic stents (SEMS) for malignant GOO, (2) covered versus uncovered SEMS for malignant GOO, and (3) endoscopic and surgical interventions for the management of benign GOO. Recommendations provided in this document were founded on the certainty of the evidence, balance of benefits and harms, considerations of patient and caregiver preferences, resource utilization, and cost-effectiveness.",

author = "{ASGE Standards of Practice Committee} and {(ASGE Standards of Practice Committee Chair, 2017-2020)} and Jue, {Terry L.} and Storm, {Andrew C.} and Mariam Naveed and Fishman, {Douglas S.} and Qumseya, {Bashar J.} and McRee, {Autumn J.} and Truty, {Mark J.} and Khashab, {Mouen A.} and Deepak Agrawal and Mohammed Al-Haddad and Amateau, {Stuart K.} and Buxbaum, {James L.} and Calderwood, {Audrey H.} and John DeWitt and DiMaio, {Christopher J.} and Fujii-Lau, {Larissa L.} and Gurudu, {Suryakanth R.} and Jamil, {Laith H.} and Kwon, {Richard S.} and Law, {Joanna K.} and Lee, {Jeffrey K.} and Swati Pawa and Sawhney, {Mandeep S.} and Thosani, {Nirav C.} and Julie Yang and Wani, {Sachin B.}",

note = "Funding Information: The following authors disclosed financial relationships: A. C. Storm: Consultant for Apollo Endosurgery US Inc, Endo-TAGSS, and Enterasense; data and safety monitoring support from Erbe USA Inc. and GI Dynamics. D. S. Fishman: Contributor payment support for intellectual property from UpToDate. M. A. Khashab: Consultant for BSCI, Olympus, and Medtronic. M. Al-Haddad: Research and teaching support from Boston Scientific. S. K. Amateau: Consultant for Boston Scientific Corporation, Cook Medical LLC, Endo-Therapeutics, Hemostasis LLC, Merit Medical Systems Inc, Olympus Corporation of the Americas, and STERIS Corporation. J. L. Buxbaum: Consultant for Boston Scientific Corporation, Eagle Pharmaceuticals, Inc, Cook Medical LLC, and Olympus America Inc; grant support from Medtronic USA, Inc and Olympus America Inc. C. J. DiMaio: Consultant for AbbVie, Boston Scientific Corporation, and Covidien. L. L. Fujii-Lau: Travel compensation from Ovesco. S. R. Gurudu: Research grant from Gilead Pharmaceuticals. L. H. Jamil: Consultant and speaker for Aries Pharmaceutical. M. S. Sawhney: Stockholder with Allurion Technology, Inc. N. C. Thosani: Consultant for Boston Scientific Corporation, Covidien, and Pentax of America, Inc. J. Yang: Consultant for Olympus. S. B. Wani: Consultant for Boston Scientific, Medtronic, and Interpace; advisory board member for Cernostics. Publisher Copyright: {\textcopyright} 2021 American Society for Gastrointestinal Endoscopy",

year = "2021",

month = feb,

day = "1",

doi = "10.1016/j.gie.2020.07.063",

language = "English (US)",

volume = "93",

pages = "309--322.e4",

journal = "Gastrointestinal Endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction

AU - ASGE Standards of Practice Committee

AU - (ASGE Standards of Practice Committee Chair, 2017-2020)

AU - Jue, Terry L.

AU - Storm, Andrew C.

AU - Naveed, Mariam

AU - Fishman, Douglas S.

AU - Qumseya, Bashar J.

AU - McRee, Autumn J.

AU - Truty, Mark J.

AU - Khashab, Mouen A.

AU - Agrawal, Deepak

AU - Al-Haddad, Mohammed

AU - Amateau, Stuart K.

AU - Buxbaum, James L.

AU - Calderwood, Audrey H.

AU - DeWitt, John

AU - DiMaio, Christopher J.

AU - Fujii-Lau, Larissa L.

AU - Gurudu, Suryakanth R.

AU - Jamil, Laith H.

AU - Kwon, Richard S.

AU - Law, Joanna K.

AU - Lee, Jeffrey K.

AU - Pawa, Swati

AU - Sawhney, Mandeep S.

AU - Thosani, Nirav C.

AU - Yang, Julie

AU - Wani, Sachin B.

N1 - Funding Information: The following authors disclosed financial relationships: A. C. Storm: Consultant for Apollo Endosurgery US Inc, Endo-TAGSS, and Enterasense; data and safety monitoring support from Erbe USA Inc. and GI Dynamics. D. S. Fishman: Contributor payment support for intellectual property from UpToDate. M. A. Khashab: Consultant for BSCI, Olympus, and Medtronic. M. Al-Haddad: Research and teaching support from Boston Scientific. S. K. Amateau: Consultant for Boston Scientific Corporation, Cook Medical LLC, Endo-Therapeutics, Hemostasis LLC, Merit Medical Systems Inc, Olympus Corporation of the Americas, and STERIS Corporation. J. L. Buxbaum: Consultant for Boston Scientific Corporation, Eagle Pharmaceuticals, Inc, Cook Medical LLC, and Olympus America Inc; grant support from Medtronic USA, Inc and Olympus America Inc. C. J. DiMaio: Consultant for AbbVie, Boston Scientific Corporation, and Covidien. L. L. Fujii-Lau: Travel compensation from Ovesco. S. R. Gurudu: Research grant from Gilead Pharmaceuticals. L. H. Jamil: Consultant and speaker for Aries Pharmaceutical. M. S. Sawhney: Stockholder with Allurion Technology, Inc. N. C. Thosani: Consultant for Boston Scientific Corporation, Covidien, and Pentax of America, Inc. J. Yang: Consultant for Olympus. S. B. Wani: Consultant for Boston Scientific, Medtronic, and Interpace; advisory board member for Cernostics. Publisher Copyright: © 2021 American Society for Gastrointestinal Endoscopy

PY - 2021/2/1

Y1 - 2021/2/1

N2 - This American Society for Gastrointestinal Endoscopy guideline provides evidence-based recommendations for the endoscopic management of gastric outlet obstruction (GOO). We applied the Grading of Recommendations, Assessment, Development and Evaluation methodology to address key clinical questions. These include the comparison of (1) surgical gastrojejunostomy to the placement of self-expandable metallic stents (SEMS) for malignant GOO, (2) covered versus uncovered SEMS for malignant GOO, and (3) endoscopic and surgical interventions for the management of benign GOO. Recommendations provided in this document were founded on the certainty of the evidence, balance of benefits and harms, considerations of patient and caregiver preferences, resource utilization, and cost-effectiveness.

AB - This American Society for Gastrointestinal Endoscopy guideline provides evidence-based recommendations for the endoscopic management of gastric outlet obstruction (GOO). We applied the Grading of Recommendations, Assessment, Development and Evaluation methodology to address key clinical questions. These include the comparison of (1) surgical gastrojejunostomy to the placement of self-expandable metallic stents (SEMS) for malignant GOO, (2) covered versus uncovered SEMS for malignant GOO, and (3) endoscopic and surgical interventions for the management of benign GOO. Recommendations provided in this document were founded on the certainty of the evidence, balance of benefits and harms, considerations of patient and caregiver preferences, resource utilization, and cost-effectiveness.

UR - http://www.scopus.com/inward/record.url?scp=85095875236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095875236&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2020.07.063

DO - 10.1016/j.gie.2020.07.063

M3 - Article

C2 - 33168194

AN - SCOPUS:85095875236

SN - 0016-5107

VL - 93

SP - 309-322.e4

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

IS - 2

ER -

ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction

Abstract

Bibliographical note

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this